Unlikely to cause harm — often a labeling or packaging issue.
Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testing for 12 Month Long-Term Stability.
| Brand name | DABIGATRAN ETEXILATE |
| Generic name | DABIGATRAN ETEXILATE |
| Active ingredient(s) | DABIGATRAN ETEXILATE MESYLATE |
| Distributed by / for | Major Pharmaceuticals, Indianapolis, IN 46268 |
| NDC | 0904-7254-68 |
| Full product label | Dabigatran etexilate Capsules, 110 mg, 60-count carton (6x10), Rx Only, Manufactured by: Alkem Laboratories, Mumbai, INDIA, Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, NDC 0904-7254-68. |
| Recalling firm | Ascend Laboratories, LLC |
| Distribution | USA Nationwide |
| Quantity | 1,753 cartons |
| Recall initiated | 2026-06-30 |
| Report date | 2026-07-29 |
| Recall completed | — |
| Recall number | D-0735-2026 |
| Classification | Class III |
| FDA status | Ongoing |
| Origin on file | Bedminster NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗